Juho Jalkanen, CEO of Faron Pharma, discusses the importance of addressing unmet medical needs in cancer through breaking treatment resistance and developing long-term solutions. In Vivo questions the current progress of their lead asset BEXMAB and its potential moving forward.

A “Game Changer” For The High-Risk MDS Patient Population

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

Share A “Game Changer” For The High-Risk MDS Patient Population

Sign up to save your podcasts

A “Game Changer” For The High-Risk MDS Patient Population

A “Game Changer” For The High-Risk MDS Patient Population

More shows like Citeline Podcasts

Marketplace Tech

WSJ Your Money Briefing

WSJ What’s News

Bloomberg Intelligence

HBR IdeaCast

How to Be Awesome at Your Job

GZERO World with Ian Bremmer

The Readout Loud

Thoughts on the Market

The Journal.

The Next Big Idea

BioCentury This Week

Coaching Real Leaders

Biotech Hangout

HBR On Leadership